Drug Trial Radar · NCT04097821
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
45
Actual
Start
Sep 26, 2019
Primary completion
May 3, 2023
Study completion Aug 28, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to investigate the safety, pharmacokinetics and preliminary efficacy of combination treatment of ruxolitinib with 5 novel compounds: siremadlin, crizanlizumab, sabatolimab, rineterkib and NIS793 in myelofibrosis (MF) subjects.
Conditions
- Myelofibrosis
Interventions
RuxolitinibDrug
5 mg tablets for oral use
SiremadlinDrug
10 mg, 20 mg, or 40 mg capsules for oral use
CrizanlizumabDrug
100 mg/10 mL concentrate for infusion for intravenous use
SabatolimabDrug
100 mg/mL or 400 mg/4 mL concentrate for infusion for intravenous use
RineterkibDrug
100 mg capsule for oral use
NIS793Drug
700 mg/7 mL concentrate for infusion for intravenous use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Dose Limiting Toxicities Within the First 2 Cycles in Part 1Time frame: Baseline to the end of Cycle 2 (6 or 8 weeks)
- Response Rate at the End of Cycle 6 or Cycle 8 in Part 1Time frame: Baseline to the end of Cycle 6 or 8 (24 weeks)
Locations
22 sites in 13 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Adelaide, South Australia, Australia
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Copenhagen, Denmark
Novartis Investigative Site
Freiburg im Breisgau, Germany
Novartis Investigative Site
Greifswald, Germany
Novartis Investigative Site
Jena, Germany
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Florence, FI, Italy
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Alicante, Spain
Novartis Investigative Site
Las Palmas de Gran Canaria, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Salamanca, Castille and León, Spain
Novartis Investigative Site
Stockholm, Sweden
Novartis Investigative Site
Sankt Gallen, Switzerland
Novartis Investigative Site
Zurich, Switzerland
Novartis Investigative Site
Kocaeli, Turkey (Türkiye)
Novartis Investigative Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.